Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Vergote I, et al. Among authors: makker v. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5. J Clin Oncol. 2023. PMID: 37669480 Clinical Trial.
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. Li BT, et al. Among authors: makker v. Cancer Discov. 2020 May;10(5):674-687. doi: 10.1158/2159-8290.CD-20-0215. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213539 Free PMC article.
Optimizing immunotherapy for gynecologic cancers.
Rubinstein MM, Makker V. Rubinstein MM, et al. Among authors: makker v. Curr Opin Obstet Gynecol. 2020 Feb;32(1):1-8. doi: 10.1097/GCO.0000000000000603. Curr Opin Obstet Gynecol. 2020. PMID: 31833942 Free PMC article. Review.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orlowski R, Sachdev P, Shumaker R, Casado Herraez A. Makker V, et al. J Clin Oncol. 2020 Sep 10;38(26):2981-2992. doi: 10.1200/JCO.19.02627. Epub 2020 Mar 13. J Clin Oncol. 2020. PMID: 32167863 Free PMC article. Clinical Trial.
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Rubinstein MM, Grisham RN, Cadoo K, Kyi C, Tew WP, Friedman CF, O'Cearbhaill RE, Zamarin D, Zhou Q, Iasonos A, Nikolovski I, Xu H, Soldan KN, Caird I, Martin M, Guillen J, Eid KT, Aghajanian C, Makker V. Rubinstein MM, et al. Among authors: makker v. Gynecol Oncol. 2021 Jan;160(1):71-76. doi: 10.1016/j.ygyno.2020.10.019. Epub 2020 Nov 1. Gynecol Oncol. 2021. PMID: 33139041 Free PMC article. Clinical Trial.
Bevacizumab in advanced endometrial cancer.
Rubinstein MM, Dickinson S, Narayan P, Zhou Q, Iasonos A, Ma W, Lakhman Y, Makker V. Rubinstein MM, et al. Among authors: makker v. Gynecol Oncol. 2021 Jun;161(3):720-726. doi: 10.1016/j.ygyno.2021.04.016. Epub 2021 Apr 22. Gynecol Oncol. 2021. PMID: 33894982 Free PMC article.
112 results